Management of relapsed and refractory multiple myeloma in modern times: Incorporating new agents into decision-making

Charles A. Clark, Robert F. Cornell, Emma Scott, Jae Chung, Luciano J. Costa

Research output: Contribution to journalReview article

4 Scopus citations

Abstract

Although upfront treatment of multiple myeloma has become more effective, relapses are the norm, often driven by the emergence of a genetically divergent clone selected by the initial therapy. Recent trials have demonstrated the safety and efficacy of combination therapy also in the relapsed and refractory setting and supported the regulatory approval of several new agents including new proteasome inhibitors, immunomodulatory agents, and monoclonal antibodies. We provide a detailed summary of recent practice-changing trials in relapsed and refractory MM and share a practical approach to assimilate disease and patient-features into treatment decision. Am. J. Hematol. 91:1044–1051, 2016.

Original languageEnglish (US)
Pages (from-to)1044-1051
Number of pages8
JournalAmerican Journal of Hematology
Volume91
Issue number10
DOIs
StatePublished - Oct 1 2016

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Management of relapsed and refractory multiple myeloma in modern times: Incorporating new agents into decision-making'. Together they form a unique fingerprint.

  • Cite this